Jasper Therapeutics Inc [JSPR] stock is trading at $1.77, up 2.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The JSPR shares have gain 12.03% over the last week, with a monthly amount drifted -0.56%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jasper Therapeutics Inc [NASDAQ: JSPR] stock has seen the most recent analyst activity on July 08, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform but kept the price target unchanged to $5 for it. Previously, BMO Capital Markets downgraded its rating to Market Perform on July 08, 2025, and kept the price target unchanged to $4. On July 07, 2025, downgrade downgraded it’s rating to Mkt Perform. Cantor Fitzgerald downgraded its rating to a Neutral. UBS initiated its recommendation with a Buy and recommended $38 as its price target on February 13, 2025. BMO Capital Markets started tracking with an Outperform rating for this stock on December 06, 2024, and assigned it a price target of $63. In a note dated September 09, 2024, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
Jasper Therapeutics Inc [JSPR] stock has fluctuated between $1.39 and $23.37 over the past year. Currently, Wall Street analysts expect the stock to reach $41.67 within the next 12 months. Jasper Therapeutics Inc [NASDAQ: JSPR] shares were valued at $1.77 at the most recent close of the market. An investor can expect a potential return of 2254.24% based on the average JSPR price forecast.
Analyzing the JSPR fundamentals
Gross Profit Margin for this corporation currently stands at -0.42% with Operating Profit Margin at -80.11%, Pretax Profit Margin comes in at -77.45%, and Net Profit Margin reading is -54.68%. To continue investigating profitability, this company’s Return on Assets is posted at -1.38, Equity is -1.22 and Total Capital is -3.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6967 points at the first support level, and at 1.6233 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8167, and for the 2nd resistance point, it is at 1.8633.
Ratios To Look Out For
For context, Jasper Therapeutics Inc’s Current Ratio is 2.59. On the other hand, the Quick Ratio is 2.59, and the Cash Ratio is 1.93.
Transactions by insiders
Recent insider trading involved WIGGANS THOMAS G, Director, that happened on Sep 22 ’25 when 41000.0 shares were purchased. Director, Lucas Svetlana completed a deal on Sep 22 ’25 to buy 20000.0 shares. Meanwhile, President and CEO MARTELL RON bought 41000.0 shares on Sep 22 ’25.
